Literature DB >> 35578052

Mutational spectrum of BRCA1/2 genes in Moroccan patients with hereditary breast and/or ovarian cancer, and review of BRCA mutations in the MENA region.

Siham Chafai Elalaoui1,2, Fatima Zohra Laarabi3, Lamiae Afif4,5, Jaber Lyahyai4,5, Ilham Ratbi4,5, Imane Cherkaoui Jaouad5, Yassamine Doubaj5, Meryem Sahli5, Mouna Ouhenach5, Abdelaziz Sefiani4,5.   

Abstract

PURPOSE: Breast cancer (BC) is the most common form of female cancer around the world. BC is mostly sporadic, and rarely hereditary. These hereditary forms are mostly BRCA1- and BRCA2-associated hereditary breast and ovarian cancer syndrome. BRCA1 and BRCA2 genes are large and had some recurrent mutations specific to some populations. Through this work we analyze the most recurrent mutations in Moroccan population and compared them to a large review of other BRCA1/2 spectrum mutations in the MENA region.
METHODS: We report in this work a series of 163 unrelated patients (the largest series of Moroccan patients) with familial breast and/or ovarian cancer, selected among patients referred to our oncogenetic outpatient clinic, from 2006 to 2021. To identify genetic variants in these two genes, different genetic analysis strategies have been carried out, using Sanger Sequencing DNA or Target Panel Sequencing.
RESULTS: Pathogenic variants were identified in 27.6% of patients. The most frequent mutation identified in our patients was the c.1310_1313delAAGA, BRCA2 (33%), and three other mutations seem more frequent in the Moroccan population (33%) of all reported patients: c.798_799delTT, BRCA1; and c.3279delC, BRCA1; and c.7234_7235insG in BRCA2 gene.
CONCLUSION: Through this work, we emphasize the importance of screening for BRCA1 and BRCA2 recurrent mutations in Moroccan patients. Other MENA (MENA: English-language acronym referring to the Middle East and North Africa region) countries had also some recurrent BRCA mutations, which will allow a fast and unexpensive first line genetic analysis and a precise molecular diagnosis. This will allow an adapted follow-up of the patients and a pre-symptomatic diagnosis of their relatives.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  BRCA1; BRCA2; MENA; Morocco; Mutation; Recurrent; Spetcrum

Mesh:

Substances:

Year:  2022        PMID: 35578052     DOI: 10.1007/s10549-022-06622-3

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  40 in total

Review 1.  Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage.

Authors:  Kiyotsugu Yoshida; Yoshio Miki
Journal:  Cancer Sci       Date:  2004-11       Impact factor: 6.716

2.  BRCA1 and BRCA2 germline mutations in Moroccan breast/ovarian cancer families: novel mutations and unclassified variants.

Authors:  Amal Tazzite; Hassan Jouhadi; Sellama Nadifi; Paolo Aretini; Elisabetta Falaschi; Anita Collavoli; Abdellatif Benider; Maria Adelaide Caligo
Journal:  Gynecol Oncol       Date:  2012-03-13       Impact factor: 5.482

3.  First application of next-generation sequencing in Moroccan breast/ovarian cancer families and report of a novel frameshift mutation of the BRCA1 gene.

Authors:  Farah Jouali; Fatima-Zahra Laarabi; Nabila Marchoudi; Ilham Ratbi; Siham Chafai Elalaoui; Houria Rhaissi; Jamal Fekkak; Abdelaziz Sefiani
Journal:  Oncol Lett       Date:  2016-06-16       Impact factor: 2.967

Review 4.  BRCA genetic screening in Middle Eastern and North African: mutational spectrum and founder BRCA1 mutation (c.798_799delTT) in North African.

Authors:  Abdelilah Laraqui; Nancy Uhrhammer; Hicham E L Rhaffouli; Yassine Sekhsokh; Idriss Lahlou-Amine; Tahar Bajjou; Farida Hilali; Jamila El Baghdadi; Abderrahmane Al Bouzidi; Youssef Bakri; Said Amzazi; Yves-Jean Bignon
Journal:  Dis Markers       Date:  2015-02-28       Impact factor: 3.434

5.  Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women.

Authors:  Timothy R Rebbeck; Tara M Friebel; Nandita Mitra; Fei Wan; Stephanie Chen; Irene L Andrulis; Paraskevi Apostolou; Norbert Arnold; Banu K Arun; Daniel Barrowdale; Javier Benitez; Raanan Berger; Pascaline Berthet; Ake Borg; Saundra S Buys; Trinidad Caldes; Jonathan Carter; Jocelyne Chiquette; Kathleen B M Claes; Fergus J Couch; Cezary Cybulski; Mary B Daly; Miguel de la Hoya; Orland Diez; Susan M Domchek; Katherine L Nathanson; Katarzyna Durda; Steve Ellis; D Gareth Evans; Lenka Foretova; Eitan Friedman; Debra Frost; Patricia A Ganz; Judy Garber; Gord Glendon; Andrew K Godwin; Mark H Greene; Jacek Gronwald; Eric Hahnen; Emily Hallberg; Ute Hamann; Thomas V O Hansen; Evgeny N Imyanitov; Claudine Isaacs; Anna Jakubowska; Ramunas Janavicius; Katarzyna Jaworska-Bieniek; Esther M John; Beth Y Karlan; Bella Kaufman; KConFab Investigators; Ava Kwong; Yael Laitman; Christine Lasset; Conxi Lazaro; Jenny Lester; Niklas Loman; Jan Lubinski; Siranoush Manoukian; Gillian Mitchell; Marco Montagna; Susan L Neuhausen; Heli Nevanlinna; Dieter Niederacher; Robert L Nussbaum; Kenneth Offit; Edith Olah; Olufunmilayo I Olopade; Sue Kyung Park; Marion Piedmonte; Paolo Radice; Christine Rappaport-Fuerhauser; Matti A Rookus; Caroline Seynaeve; Jacques Simard; Christian F Singer; Penny Soucy; Melissa Southey; Dominique Stoppa-Lyonnet; Grzegorz Sukiennicki; Csilla I Szabo; Mariella Tancredi; Manuel R Teixeira; Soo-Hwang Teo; Mary Beth Terry; Mads Thomassen; Laima Tihomirova; Marc Tischkowitz; Amanda Ewart Toland; Aleksandra Toloczko-Grabarek; Nadine Tung; Elizabeth J van Rensburg; Danylo Villano; Shan Wang-Gohrke; Barbara Wappenschmidt; Jeffrey N Weitzel; Jamal Zidan; Kristin K Zorn; Lesley McGuffog; Douglas Easton; Georgia Chenevix-Trench; Antonis C Antoniou; Susan J Ramus
Journal:  Breast Cancer Res       Date:  2016-11-11       Impact factor: 6.466

6.  High frequency of the recurrent c.1310_1313delAAGA BRCA2 mutation in the North-East of Morocco and implication for hereditary breast-ovarian cancer prevention and control.

Authors:  Fatima-Zahra Laarabi; Ilham Ratbi; Siham Chafai Elalaoui; Loubna Mezzouar; Yassamine Doubaj; Laila Bouguenouch; Karim Ouldim; Noureddine Benjaafar; Abdelaziz Sefiani
Journal:  BMC Res Notes       Date:  2017-06-02

7.  Next-generation sequencing of BRCA1 and BRCA2 genes in Moroccan prostate cancer patients with positive family history.

Authors:  Fatiha Salmi; Fatima Maachi; Amal Tazzite; Rachid Aboutaib; Jamal Fekkak; Houssine Azeddoug; Hassan Jouhadi
Journal:  PLoS One       Date:  2021-07-09       Impact factor: 3.240

8.  Mutation screening of the BRCA1 gene in early onset and familial breast/ovarian cancer in Moroccan population.

Authors:  Abdelilah Laraqui; Nancy Uhrhammer; Idriss Lahlou-Amine; Hicham El Rhaffouli; Jamila El Baghdadi; Mohamed Dehayni; Rahali Driss Moussaoui; Mohamed Ichou; Yassir Sbitti; Abderrahman Al Bouzidi; Said Amzazi; Yves-Jean Bignon
Journal:  Int J Med Sci       Date:  2012-12-10       Impact factor: 3.738

9.  Contribution of BRCA1 and BRCA2 germline mutations to early onset breast cancer: a series from north of Morocco.

Authors:  Joaira Bakkach; Mohamed Mansouri; Touria Derkaoui; Ali Loudiyi; ElMostafa El Fahime; Amina Barakat; Naima Ghailani Nourouti; Jaime Martinez De Villarreal; Carlos Cortijo Bringas; Mohcine Bennani Mechita
Journal:  BMC Cancer       Date:  2020-09-07       Impact factor: 4.430

10.  Screening of BRCA1/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC).

Authors:  Fatima Zahra El Ansari; Farah Jouali; Nabila Marchoudi; Mohcine Mechita Bennani; Naima Nourouti Ghailani; Amina Barakat; Jamal Fekkak
Journal:  BMC Cancer       Date:  2020-08-10       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.